التفاصيل البيبلوغرافية
| العنوان: |
Treatment outcome in transplant ineligible patients with multiple myeloma: A single center real-life experience. |
| المؤلفون: |
Uysal, Ayse, Merter, Mustafa, Sen, Askin |
| المصدر: |
Annals of Medical of Research; Sep2022, Vol. 29 Issue 9, p925-929, 5p |
| مصطلحات موضوعية: |
MULTIPLE myeloma treatment, PROTEASOME inhibitors, CYCLOPHOSPHAMIDE, DEXAMETHASONE, PATIENTS' attitudes |
| مستخلص: |
Aim: The objective of this study is to assess the choice of first-line and other line options, treatment outcome, and survival effects in transplant-ineligible patients with multiple myeloma (MM) in the novel anti-myeloma agents’ era. Materials and Methods: Forty-five transplant-ineligible patients with MM were evaluated retrospectively. Patients’ characteristics, disease score, cytogenetic, LDH, treatment lines, treatment protocol, treatment response, and survival status at the last follow-up were examined. Results: The median age was 71 (range, 60-85) years. Thirty-nine (86.6%) patients were over 65 years old, 32 (71.1%) of them had poor performance scores and 25 (55.6%) of them had comorbidity. The most used induction regimen was bortezomib plus cyclophosphamide plus dexamethasone (n:33;73.3%). The overall response rate was detected in 30 (66.6%) patients in overall induction regimens. The maintenance treatment was applied to 14 (31.1%) patients after induction treatment and lenalidomide plus dexamethasone (Rd) was used for maintenance treatment. Twelve (85.8%) patients are still on maintenance treatment with VGPR or better response. The most used second-line regimen was Rd (n:12; 46.1%) and bortezomib plus lenalidomide plus dexamethasone (n:9;34.6%). The median follow-up period was evaluated as 36 (1-81) months. After the first-line treatment, progression-free survival was found to be 12 (0-64) months. The median overall survival (OS) was 17 (1-81) months. Twelve patients are alive without progression. The median OS was significantly shorter among patients with high LDH at the time of diagnosis than patients with normal LDH [28 (12.06–43.94) months vs 47.21 (21.23–50.77) months, respectively] (p=0.037). The median PFS was not reached in patients with maintenance treatment, in patients without maintenance treatment the median PFS was detected 23 (10-35.9) months (p=0.058). Conclusion: An induction regimen should be well chosen to ensure a deep and prolonged response, and maintenance treatment should be preferred in suitable patients to maintain response in transplant-ineligible patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Medical of Research is the property of Annals of Medical Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |